These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10588838)

  • 1. Jeune syndrome and liver disease: report of three cases treated with ursodeoxycholic acid.
    Labrune P; Fabre M; Trioche P; Estournet-Mathiaud B; Grangeponte MC; Rambaud C; Maurage C; Bernard O
    Am J Med Genet; 1999 Dec; 87(4):324-8. PubMed ID: 10588838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.
    Santos VN; Lanzoni VP; Szejnfeld J; Shigueoka D; Parise ER
    Braz J Med Biol Res; 2003 Jun; 36(6):723-9. PubMed ID: 12792701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of ursodeoxycholic acid on serum gamma-GTP in patients with biliary atresia following living related liver transplantation.
    Tanaka H; Kita Y; Kawarasaki H; Harihara Y; Ito M; Mizuta K; Terawaki K; Nakahara S; Hashizume K; Makuuchi M
    Transplant Proc; 1998 Nov; 30(7):3326-7. PubMed ID: 9838470
    [No Abstract]   [Full Text] [Related]  

  • 5. Flare-up of autoimmune hepatitis after delivery in a patient with primary biliary cirrhosis: postpartum overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis.
    Ohba K; Omagari K; Kusakari C; Kadokawa Y; Hayashida K; Takeshima F; Mizuta Y; Murata I; Nakanuma Y; Kohno S
    Dig Dis Sci; 2005 Jan; 50(1):201-6. PubMed ID: 15712661
    [No Abstract]   [Full Text] [Related]  

  • 6. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
    Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful renal transplantation in Jeune syndrome type 2.
    Amirou M; Bourdat-Michel G; Pinel N; Huet G; Gaultier J; Cochat P
    Pediatr Nephrol; 1998 May; 12(4):293-4. PubMed ID: 9655360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
    Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of primary biliary cholangitis in a "teen" male patient.
    Muratori P; Lenzi M; Muratori L
    Clin Res Hepatol Gastroenterol; 2019 Apr; 43(2):e20-e21. PubMed ID: 30145280
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatic manifestations of Jeune syndrome (asphyxiating thoracic dystrophy).
    Yerian LM; Brady L; Hart J
    Semin Liver Dis; 2003 May; 23(2):195-200. PubMed ID: 12800072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
    Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
    J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis.
    Joshita S; Umemura T; Ota M; Tanaka E
    J Hepatol; 2014 Dec; 61(6):1443-5. PubMed ID: 25152209
    [No Abstract]   [Full Text] [Related]  

  • 14. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis".
    Trivedi PJ; Bruns T; Li KK; Hirschfield GM
    J Hepatol; 2014 Dec; 61(6):1445-6. PubMed ID: 25152206
    [No Abstract]   [Full Text] [Related]  

  • 16. Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.
    Cheng K; Ashby D; Smyth R
    J R Soc Med; 1997; 90 Suppl 31(Suppl 31):6-12. PubMed ID: 9204005
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of ursodeoxycholic acid in liver diseases.
    Kumar D; Tandon RK
    J Gastroenterol Hepatol; 2001 Jan; 16(1):3-14. PubMed ID: 11206313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.
    Leuschner M; Dietrich CF; You T; Seidl C; Raedle J; Herrmann G; Ackermann H; Leuschner U
    Gut; 2000 Jan; 46(1):121-6. PubMed ID: 10601067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.